High population immunity from prior infections and vaccinations, combined with reduced viral severity and no evidence of emerging lineages meeting WHO criteria for variants of concern, underpins trader consensus favoring no new COVID variant of concern before 2027. As of mid-2026, dominant strains such as XFG and NB.1.8.1 remain classified only as variants under monitoring, with limited antigenic drift from JN.1 descendants and no marked increases in transmissibility or hospitalizations. Surveillance data through August show declining or stable test positivity rates alongside ongoing but contained circulation of divergent lineages like BA.3.2. Vaccine strain selections for 2026-2027 continue to target prevalent subvariants effectively, and historical patterns indicate that major designations require substantial public health impact unlikely to materialize in the remaining months of 2026.